Covid-19 roundup: US and Pfizer strike deal for 100M more doses; NIH and partners cut critically ill patients out of blood thinner trial

Nicole DeFeudis

Editor

The US government has sealed a deal with Pfizer and BioNTech for 100 million additional doses of their Covid-19 vaccine, doubling the country’s dose order …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: US and Pfizer strike deal for 100M more doses; NIH and partners cut critically ill patients out of blood thinner trial

Nicole DeFeudis

Editor

Sign up to read this article for free.

Sanofi, OpenAI, Formation Bio debut patient recruiting tool, will use in Phase 3 multiple sclerosis studies

Maze's ALS spinout Trace Neuroscience raises $101M for ALS and neuro work

Updated: AstraZeneca, Daiichi Sankyo replace lung cancer filing for Enhertu successor

Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use

Roche teams with Flare Therapeutics on transcription factors

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Covid-19 roundup: US and Pfiz­er strike deal for 100M more dos­es; NIH and part­ners cut crit­i­cal­ly ill pa­tients out of blood thin­ner tri­al

Nicole DeFeudis

Editor

Sign up to read this article for free.

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

Roche teams with Flare Ther­a­peu­tics on tran­scrip­tion fac­tors

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Covid-19 roundup: US and Pfizer strike deal for 100M more doses; NIH and partners cut critically ill patients out of blood thinner trial

Sanofi, OpenAI, Formation Bio debut patient recruiting tool, will use in Phase 3 multiple sclerosis studies

Maze's ALS spinout Trace Neuroscience raises $101M for ALS and neuro work

Updated: AstraZeneca, Daiichi Sankyo replace lung cancer filing for Enhertu successor

Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use

Roche teams with Flare Therapeutics on transcription factors

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?